Cart
sales@molnova.com
Sarizotan HCl
CAS No. 195068-07-6
Sarizotan HCl( —— )
Catalog No. M36321 CAS No. 195068-07-6
Sarizotan HCl (EMD 128130 HCl) is an hERG channel inhibitor and 5-hydroxytryptamine 5-HT1A receptor agonist with potential antidepressant effects for the study of Parkinson's Dyskinesia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSarizotan HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionSarizotan HCl (EMD 128130 HCl) is an hERG channel inhibitor and 5-hydroxytryptamine 5-HT1A receptor agonist with potential antidepressant effects for the study of Parkinson's Dyskinesia.
-
DescriptionSarizotan HCl (EMD 128130 HCl) is an hERG channel inhibitor and 5-hydroxytryptamine 5-HT1A receptor agonist with potential antidepressant effects for the study of Parkinson's Dyskinesia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetHER/HSP
-
RecptorHER | 5-HT Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number195068-07-6
-
Formula Weight384.87
-
Molecular FormulaC22H22ClFN2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NC[C@@H]1OC=2C(CC1)=CC=CC2)C3=CC(=CN=C3)C4=CC=C(F)C=C4.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
BMS 599626 2HCl
BMS-599626 (AC480) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM) ~8-fold less potent to HER4 >100-fold to Lck VEGFR2 c-Kit MET etc.
-
Zongertinib
Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (TKD).
-
Pertuzumab
Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.
